ARTICLE | Company News
J&J, PATH in HIV deal
September 26, 2013 1:11 AM UTC
The Janssen Research & Development Ireland unit of Johnson & Johnson (NYSE:JNJ) granted the Program for Appropriate Technology in Health (PATH) (Seattle, Wash.) non-exclusive, royalty-free rights to a long-acting injectable formulation of rilpivirine as a potential pre-exposure prophylaxis (PrEP) for HIV infection. The nonprofit intends to start Phase II trials next year in collaboration with partners including the HIV Prevention Trials Network and the Division of AIDS at NIH. PATH said the Bill & Melinda Gates Foundation will fund development to establish the viability of the product. ...